Navigation Links
Third Wave reports another loss, stronger sales

Madison, Wis. - Third Wave Technologies, Inc. reported a net loss of $4.7 million, or 11 cents a share, for the second quarter of 2006, but robust sales have prompted the company to revise year-end revenue projections upward in a key market.

Third Wave, which develops molecular diagnostic reagents for DNA and RNA analysis applications, reported that revenue rose by 15 p......

Full article >>> the second quarter, compared to $11.5 million for the same period of 2005. Third Wave's pro forma total operating expenses for the second quarter of 2005, including stock compensation costs, were $13.2 million.

For the first six months of 2006, total operating expenses were $24.4 million, compared to $23.1 million for the same period of 2005. The company's pro forma total operating expens......

Full article >>> tection of chlamydia and gonorrhea in 2007. Testing for HPV, chlamydia, and gonorrhea accounts for more than 20 percent of the molecular diagnostic testing market.

As a result, Third Wave has raised its projection on clinical molecular diagnostic revenue to $20-21 million for 2006.

Another new product is a next generation version of Invader. Based on the results of external evalu......

Full article >>>
'"/>

Source:wistechnology.com By Joe Vanden Plas 07/25/06


Related biology technology :

1. Third Wave files countersuit vs. Digene in patent case
2. Third Wave reports net loss of $18.9M for 2006
3. Stratagene to pay Third Wave $10.75M in patent case
4. Third Wave responds to Digene patent lawsuit
5. Third Wave seeks approval of Cystic Fibrosis test
6. Third Wave Technologies to raise $14.9M through private debt
7. Third Wave reports $5.2M third quarter loss
8. Napier joins board of Third Wave Technologies
9. Third Waves revenues rebound
10. Third Wave reports clinical growth, continued loss
11. Third Wave announces two senior management appointments
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/4/2016)... WHIPPANY, N.J. , May 4, 2016 /PRNewswire/ ... evaluating its oncology compound Stivarga ® (regorafenib) ... hepatocellular carcinoma (HCC) has met its primary endpoint ... The study, called RESORCE, evaluated the efficacy and ... disease has progressed after treatment with sorafenib. The ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... biotechnology to help treat hormonal and stress related hair loss. With patent-pending formulas ... hearts of key opinion leaders in the medical and salon channels nationwide. ...
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs from biotech, ... 31st and June 1st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
(Date:5/3/2016)... 3, 2016 - And Other ... Producers of Those Competitor Biologics  - Biosimilar ... and Prospects ,  Who are the most ... what are their sales potentials? Discover, in our updated ... trends, opportunities and revenue forecasting. Visiongain,s ...
Breaking Biology Technology:
(Date:3/9/2016)... -- This BCC Research report provides an overview of ... (RNA Seq) market for the years 2015, 2016 and ... data analysis, and services. Use this report ... such as RNA-Sequencing tools and reagents, RNA-Sequencing data analysis, ... segment and forecast their market growth, future trends and ...
(Date:3/3/2016)...  FlexTech, a SEMI Strategic Association Partner, awarded five ... Development, Leadership in Education, and, in a category new ... year of the FLEXI Awards and the winners ... past years . Judging was done on a ... criteria, by a panel of non-affiliated, independent, industry experts. ...
(Date:3/2/2016)... , March 2, 2016 ... of the "Global Biometrics as a ... offering. --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ... "Global Biometrics as a Service Market 2016-2020" ... --> Research and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ...
Breaking Biology News(10 mins):